Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study

Objective This study aimed to evaluate the safety and tolerability of OP-724, a CREB-binding protein/β-catenin inhibitor, in patients with advanced primary biliary cholangitis (PBC).Design An open-label, non-randomised, phase 1 trial was conducted at two hospitals in Japan. Patients with advanced PB...

Full description

Saved in:
Bibliographic Details
Main Authors: Eiichi Ogawa, Atsushi Tanaka, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Masamichi Kimura, Jun Imamura, Masanao Saio, Yoshihiro Ikura, Kouichi Miura, Ichiro Ieiri, Kiminori Kimura
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/9/1/e001001.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopengastro.bmj.com/content/9/1/e001001.full

Similar Items